ArticleDiagnostic and interventional radiology (Ankara, Turkey)2026
Comparison of changes in dynamic contrast-enhanced magnetic resonance imaging and flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters from baseline to post-neoadjuvant therapy in predicting pathological response in breast cancer.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to compare the value of differences (Δ) in parameters obtained via both dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography (
methodsA total of 109 patients who underwent both baseline and post-neoadjuvant therapy DCE-MRI and
resultsPatients with partial response demonstrated a higher rate of histologic grade 3 than those with pCR (
conclusionThe Δ CLINICAL SIGNIFICANCE: Neoadjuvant chemotherapy (NAC) response is one of the most important criteria in breast cancer prognosis. The two most important imaging modalities in breast cancer diagnosis and follow-up protocols are MRI and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.